本文選題：venetoclax + 白血病��； 參考：《中國(guó)新藥與臨床雜志》2017年03期

【摘要】：BCL-2是細(xì)胞凋亡信號(hào)途徑中的重要靶分子,發(fā)揮抑制細(xì)胞凋亡的作用。venetoclax為一種口服選擇性BCL-2抑制劑,通過(guò)與BCL-2結(jié)合,恢復(fù)腫瘤細(xì)胞的正常凋亡途徑,從而發(fā)揮抗腫瘤的作用。venetoclax已獲美國(guó)FDA批準(zhǔn)用于單獨(dú)治療曾接受過(guò)至少一種治療方案的染色體17p缺失的慢性淋巴細(xì)胞白血病患者。其常見(jiàn)的不良反應(yīng)包括中性粒細(xì)胞減少、腹瀉、惡心、貧血、血小板減少、上呼吸道感染及疲勞等。
[Abstract]:BCL-2 is an important target molecule in the signal pathway of apoptosis. Venetoclax is an oral selective BCL-2 inhibitor, which restores the normal apoptotic pathway of tumor cells by binding with BCL-2. Thus the antitumor effect of .venetoclax has been approved by the United States FDA for the treatment of chronic lymphoblastic leukemia patients with at least one chromosome 17p deletion. Common adverse effects include neutropenia, diarrhea, nausea, anemia, thrombocytopenia, upper respiratory tract infections and fatigue.
【作者單位】： 臨沂市中心醫(yī)院藥學(xué)部;
【分類(lèi)號(hào)】：R979.1
，

本文編號(hào)：1803369